Migraine sufferers in Hungary present a major epidemiological challenge with about 12% of the population affected. Authors have reviewed an extensive body of internationally published literature relative to the 5-hydroxi-triptamin receptor agonists such as the triptans. While summarising most relevant data with a view to enable physicians to choose the most effective therapy for an individual, the article also discusses the prevailing questions of efficacy, tolerability and safety. For those patients with differential-diagnostic difficulties referrals should be made to the specialized 'headache centers' of neurological departments.
|Translated title of the contribution||Triptan therapy of migraine|
|Number of pages||7|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Mar 1 2004|
ASJC Scopus subject areas